
Experts Benjamin Levy, MD, and Estelamari Rodriguez, MD, MPH, highlight current understandings of EGFR mutation classifications in the context of non–small cell lung cancer.

Estelamari Rodriguez, MD, MPH, is associate director of Community Outreach – Thoracic Oncology at Sylvester Comprehensive Cancer Center.

Experts Benjamin Levy, MD, and Estelamari Rodriguez, MD, MPH, highlight current understandings of EGFR mutation classifications in the context of non–small cell lung cancer.

A brief discussion on key barriers to molecular testing in non–small cell lung cancer and how multidisciplinary care plays a role in addressing these hurdles.

Shared perspective on the armamentarium of molecular testing assays in non–small cell lung cancer and how results can be best interpreted when selecting treatment.

Expert oncologists reflect on the current state of molecular testing in patients with non–small cell lung cancer and how it has impacted treatment pathways.

Estelamari Rodriguez, MD, MPH, discusses the benefits of the TKIs afatinib and osimertinib in patients with lung cancer with uncommon EGFR mutations.

Estelamari Rodriguez, MD, MPH, discusses the role of immunotherapy in extensive-stage small cell lung cancer.